Category Archives: Sales

How Will Accountable Care Organizations Hit Drug Sales?

By Ben Comer | Published: April 5, 2011
It’s not yet clear whether physicians will rush to form accountable care organizations (ACOs) in light of newly proposed Centers for Medicare and Medicaid Services (CMS) guidelines, which are lengthy, but pharmaceutical companies hoping to do business with ACOs will have to show that expensive brand drugs can offer not just better health outcomes, but [...]
Also posted in Legal, News, Regulatory, Strategy, healthcare | Tagged , , , , , | Leave a comment

Two 'Most Promising' New Drugs Face Setbacks in US

By Ben Comer | Published: March 22, 2011
Two of the drugs named “most promising” in Thomson Reuters’ recent quarterly report hit snags in the US, despite European approval. Those two products – AstraZeneca’s Brilique (Brilinta in the US), a blood thinner, and Pharming’s Ruconest (Rhucin in the US) – were held up during FDA’s review process. Brilique (ticagrelor), AstraZeneca’s leading pipeline drug, was [...]
Also posted in FDA, Global, R&D, Regulatory | Tagged , , , , , | Leave a comment

Big Pharma Reps Still Competing with Local Players in Emerging Markets

By Reid Paul | Published: September 15, 2010
Although pharma is an increasingly global marketplace, the relative rankings of companies are becoming more localized — with significant variations — according to a new Cegedim survey of physician attitudes towards reps in the major western markets and Brazil, India, Russia, and China. According to the International Rep Quality survey, physicians tend to favor domestic [...]
Also posted in Emerging Markets, Europe, Guest Blog, Marketing | Tagged , , , , , , | Leave a comment

New Study Shows Spike in Branded Drug Prices (Updated 8/26)

By George Koroneos | Published: August 25, 2010
The retail price of branded pharmaceuticals spiked 8.3 percent in 2009, according to a new report released by AARP on Wednesday. This is the first time AARP has measured the retail price of Rx drugs. In the past, the lobby group only tracked the wholesale manufacturers’ price of generic, branded, and specialty drugs, which is traditionally [...]
Also posted in Strategy | 2 Comments

Novartis Employees Get $250 million Payout

By Reid Paul | Published: May 19, 2010
A Federal jury in New York ruled against Novartis in a gender discrimination lawsuit, ordering the company to pay $3.36 million in compensatory damages to 12 women and $250 million in punitive damages to 5,600 others in one of the largest gender discrimination class actions in American history. The women charged that Novartis created a [...]
Also posted in Corporate Responsibility, Legal | Tagged , , , , , , | Leave a comment